The optimal use of vasoactive medications in patients with pulmonary arterial hypertension with shock remains unknown. Using a national database, we benchmarked initial vasoactive practices.
Preterm birth survivors reaching adulthood are a growing population, with bronchopulmonary dysplasia (BPD), the chronic lung disease of prematurity, common among this cohort. Infants with BPD are at increased risk for pulmonary vascular disease (PVD) including the development of pulmonary hypertension (PH).
Pulmonary hypertension (PH) is defined by elevated mean pulmonary arterial pressure (mPAP). Pulmonary vascular resistance (PVR) and SvO2 (mixed venous oxygenation), measured by right heart catheterization (RHC), are key determinants of disease severity and prognosis.
The gut microbiota has been implicated in pulmonary vascular diseases, yet a direct causal link to pulmonary embolism (PE) remains unestablished. This study aimed to investigate the causal effects of gut microbiota on PE and to explore the mediating role of circulating metabolites in this relationship.
We aimed to evaluate the role of medical therapy before and after balloon pulmonary angioplasty (BPA) for non-operable chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era.
Neonates and infants with FOXF1 mutation develop alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV), which is typically considered a uniformly fatal neonatal lung disorder due to marked hypoxemic respiratory failure with severe pulmonary hypertension (PH).
Explore how sex differences, estradiol, and oestrogen receptor α influence right ventricular angiogenesis and adaptation to pressure overload. Ketul Chaudhary and Jiajun Li share emerging research into the mechanisms that may protect right heart function in PH.
Pulmonary arterial hypertension (PAH) is a rare and progressive disease characterized by remodeling of the pulmonary vasculature, which leads to increased pulmonary artery pressure and ultimately right ventricular failure. Although Japanese guidelines recommend combination therapy, real-world data show inconsistencies in its implementation.
Level 3 cardiopulmonary exercise testing (CPET) can unmask the dynamic burden of pulmonary vascular disease (PVD), while submaximal exercise testing offers a simpler, noninvasive alternative.
Abnormal pulmonary hemodynamics during exercise may persist even after balloon pulmonary angioplasty (BPA) for inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
